CNMD, US2074101013

Eight analysts set a USD 41.40 target for CONMED stock

Published on 10/17/2026 at 21:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CONMED reports third-quarter results on October 28, 2026. CONMED stock costs USD 46.72 on October 16, 2026, down 0.89 percent on the day on the NYSE.

Analyst view and upcoming results

MarketBeat reported on October 9, 2026, that eight firms assigned CONMED an average USD 41.40 target.
CONMED is scheduled to report third-quarter 2026 results on October 28, 2026.
CONMED stock closed at USD 46.72 on October 16, 2026, down 0.89 percent on the day on the NYSE.
CONMED had a price-to-earnings ratio of 25.23 and a market capitalization of USD 1.4 billion on October 16, 2026.

CNMD, US2074101013, Illustration mit AI erstellt.

Eight research firms assigned CONMED Corporation (ISIN US2074101013) an average target of USD 41.40 on October 9, 2026, according to MarketBeat. The target lies 11.39 percent below the USD 46.72 closing price. At the last completed NYSE session, CONMED closed at USD 46.72 on October 16, 2026 at 4:00 p.m. EDT, down 0.89 percent on the day.

Results date sets the next marker

CONMED will report third-quarter 2026 financial results after the market close on October 28, 2026. The company also scheduled a conference call for 4:30 p.m. ET that day, as stated in its October 1 release. That date gives investors the next scheduled test of demand, margins and cash generation.

Price position remains below the high

CONMED's October 16 closing price stood 12.94 percent below its 52-week high of USD 53.66 and 48.60 percent above its 52-week low of USD 31.44. Trading volume was 413,965 shares against an average volume of 414,012 shares. The price therefore sat nearer the annual high than the annual low, while the daily move remained negative.

Valuation and market comparison

CONMED had a market capitalization of USD 1.4 billion and a price-to-earnings ratio of 25.23 on October 16, 2026. The valuation sits below the corresponding ratios of the two medical-device companies listed below, while CONMED's market value is much smaller.

Comparison with peers

CONMED (NYSE, USD): minus 0.89 percent, price-to-earnings ratio 25.23, market capitalization USD 1.4 billion

Stryker (NYSE, USD): plus 0.49 percent, price-to-earnings ratio 30.53, market capitalization USD 113.0 billion

Integer Holdings (NYSE, USD): minus 0.02 percent, price-to-earnings ratio 34.62, market capitalization USD 4.3 billion

The next test is October 28

CONMED's next scheduled corporate date is October 28, 2026, when management is due to discuss third-quarter results after the market close. The current valuation and the distance from the 52-week high leave the results release as the next concrete reference point for the stock.